Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to transforming the care of patients living with rare genetic diseases of obesity. The company's core business model centers on the research, development, and commercialization of peptide therapeutics that target the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating hunger and energy expenditure.
Rhythm's primary revenue source is its lead commercial product, IMCIVREE (setmelanotide), an MC4R agonist. IMCIVREE is approved in the United States and Europe for chronic weight management in adult and pediatric patients with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency, as well as Bardet-Biedl syndrome (BBS) and acquired hypothalamic obesity. In 2025, the company generated approximately $194.8 million in net product revenue entirely from global sales of IMCIVREE, with roughly 68% of sales originating in the United States and 32% from international markets.
Geographically, Rhythm operates primarily in the United States but is actively expanding its commercial footprint across Europe and other international markets. The company maintains a strong competitive position as a pioneer in precision medicine for obesity, offering the first and only FDA-approved therapies for its targeted genetic indications. In addition to commercializing IMCIVREE, Rhythm continues to invest heavily in its clinical pipeline, advancing next-generation MC4R agonists like bivamelagon and RM-718 to address a broader range of MC4R pathway disorders.
